Rising interest in CRISPR treatments

Treatments using CRISPR technology are emerging as one of the hottest medical trends in the United States – and the FDA is doing its best to promote the development.

The Oresund region aims at becoming Europe’s microbiome Mecca

The Medicon Valley Alliance’s ambition: Skåne and the Copenhagen region will become world leaders in microbiome research.

Donanemab godkänns i Storbritannien – men anses för dyrt för skattebetalarna

Eli Lillys alzheimerläkemedel donanemab godkänns i Storbritannien – men lär ändå inte bli tillgängligt för vanliga patienter. Orsaken är att behandlingen bedöms...

Höj trycket lokalt med hjälp av tryckluft

Att endast höja trycket där det behövs är både energismart och ekonomiskt.

Settlement of cancer allegations against blockbuster drug

French pharmaceutical company Sanofi has reached a principal agreement in the US on around 4,000 of the cases in which its now withdrawn blockbuster heartburn d...

Anna Törner: The clinical trial – Periscope to reality

What happens to the patients in the clinical trial is not very interesting, writes Anna Törner in a column.

Delivering drugs with small devices

There are many challenges to overcome when delivering a drug orally. Getting the drug to survive the low pH of the ventricle and being released at the correct s...

Stor kongress om framtidsutsikter igång i Lund

Vad sker i framtiden inom svensk och dansk life science? Det diskuteras i dag vid eventet The Future of Swedish and Danish Life Science i Lund.

Rickard Sandberg on this year’s Nobel Prize in Medicine: ”A key discovery”

The discovery that paved the way for the development of todays mRNA vaccines is the basis for this year’s Nobel Prize in Physiology or Medicine.

The first drugs to slow down Alzheimer’s – but what does it mean for patients?

New treatments for early Alzheimer’s are bringing hope to thousands of patients and their families. The question is, who will get the treatment, how will the ri...

The International Vaccine Institute’s office in Sweden is expanding

The International Vaccine Institute’s Stockholm office has been open for over a year. During the past year, training programmes and projects have been launched,...

Just four weeks to a concept for an emergency ventilator

The lockdown in spring 2020 meant that the majority of Festo employees had to join the ranks of those working from home. Yet within the space of just four weeks...

“Unfortunately, we are not strong when it comes to conducting clinical trials”

The number of company-initiated clinical trials conducted in Sweden has been declining in recent years. In mid-March, a government inquiry was presented that ai...

Marie Gårdmark: ”The situation is not satisfactory”

”The legislative tool-box is limited, but carrots in the form of longer exclusivity has already proven successful, this has for example increased registration o...

EU bokar 40 miljoner doser fågelinfluensavaccin

EU säkrar 40 miljoner doser vaccin mot fågelinfluensa – redan innan smittan nått Europa.

Improve your secondary battery manufacturing

SMC provides a large portfolio of products specially designed for secondary battery industry.

“You discover one thing – and then 10 new questions arise”

COVID-19, diabetes, heart disease, and the impact of dog ownership on humans are just some of multitasker Tove Fall’s areas of research. However, her current fo...

A new special edition and a new event in Copenhagen – This is happening at Life Science Sweden 2024

The new year brings new features for the readers of Life Science Sweden.

Lundabolag får brittiskt miljonbidrag för blodtest

Lundabolaget Prolight Diagnostics har fått ett statligt brittiskt bidrag på 17 miljoner kronor för fortsatt utveckling av ett blodtest som ska upptäcka eller ut...

New diagnostic test soon ready for the market

Ready-to-install solutions for the lab-on-a-chip

Design for manufacturing lab-on-a-chip devices Reducing time-to-market together

Fast Optical Sectioning of Developing Organisms and Tissue Microstructures

ZEISS Lattice SIM 3 exploits the full potential of the SIM Apotome technology.

Eli Lilly to build a USD 2.5-billion plant in Germany

US-based Eli Lilly is planning a huge investment of USD 2.5 billion, equivalent to around SEK 26.5 billion, in a new production facility in Alzey, Germany.

Bought a tablet factory – and built his own empire

In 1995, Thomas Eldered was CEO of one of Pharmacia’s factories in the Stockholm area when the Swedish pharmaceutical giant, after a takeover, decided to move i...